AMRX
$12.43
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.
Recent News
Is Amneal Pharmaceuticals (AMRX) Pricing Reflect Its DCF Gap And Recent Share Slide
If you are wondering whether Amneal Pharmaceuticals' current price really reflects what you are getting as a shareholder, this article is designed to walk you through that question clearly and calmly. The stock last closed at US$11.83, with a 10.6% decline over 7 days and a 19.5% decline over 30 days, while still sitting on a 6.6% decline year to date, a 35.2% gain over the past year, a very large gain of around 7x over three years, and a 65.0% gain over five years. Recent news flow around...
Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.
Amneal Pharmaceuticals Conference: “Amneal 2.0” Targets 2026 Growth in Biosimilars, CREXONT and AvKARE Shift
Amneal Pharmaceuticals (NASDAQ:AMRX) used a recent investor presentation to highlight momentum coming out of fiscal 2025 and outline priorities for 2026 and beyond, emphasizing growth drivers across its Affordable Medicines business, specialty portfolio, and its AvKARE distribution unit. Management
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead
Amneal’s 34% return over the past six months has outpaced the S&P 500 by 30.9%, and its stock price has climbed to $13.16 per share. This performance may have investors wondering how to approach the situation.
3 Value Stocks We’re Skeptical Of
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.